Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Prudential PLC

Prudential PLC boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,981 shares of the medical equipment provider's stock after purchasing an additional 2,936 shares during the quarter. Prudential PLC's holdings in Zimmer Biomet were worth $7,815,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ZBH. Roman Butler Fullerton & Co. bought a new stake in Zimmer Biomet during the fourth quarter worth about $473,000. Geode Capital Management LLC boosted its holdings in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after acquiring an additional 125,852 shares in the last quarter. M&T Bank Corp grew its stake in shares of Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock worth $2,884,000 after acquiring an additional 8,709 shares during the last quarter. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $7,825,000. Finally, Peddock Capital Advisors LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth about $654,000. Institutional investors own 88.89% of the company's stock.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.95% of the company's stock.

Remove Ads

Zimmer Biomet Trading Down 1.8 %

Shares of NYSE:ZBH traded down $1.89 during trading on Thursday, reaching $101.55. The company's stock had a trading volume of 1,045,334 shares, compared to its average volume of 1,613,406. The stock has a market capitalization of $20.21 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm's 50 day simple moving average is $106.54 and its two-hundred day simple moving average is $107.10. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $128.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the business earned $2.20 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZBH. Truist Financial restated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. JMP Securities reissued a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.